Abstract
We report a novel regimen for refractory post-transplant T-cell lymphoma (PTL). Our patient presented with non-Epstein-Barr virus (EBV) related, T-cell post-transplant lymphoproliferative disease (PTLD) 3.5 years after liver transplantation. Initially diagnosed as polyclonal PTLD, the disease progressed to a monoclonal, T-cell PTL that was refractory to several chemotherapy regimens but responded to a regimen consisting of fludarabine, cyclophosphamide, cytarabine, and alemtuzumab. Consolidation therapy included high-dose chemotherapy, autologous hematopoietic stem cell rescue, and radiation therapy. She remains in remission 2.5 years later. T-cell PTL is a rare disease with a poor prognosis; this regimen provides a novel, potentially curative approach for its treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 667-670 |
Number of pages | 4 |
Journal | Pediatric Blood and Cancer |
Volume | 50 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2008 |
Keywords
- Chemo-immunotherapy
- Post-transplant lymphoproliferative disorder
- T-cell lymphoma
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology